RESUMO
PURPOSE: Therapy for cancer-associated venous thromboembolism (VTE) includes long-term anticoagulation, which may have substantial impact on the health-related quality of life (HRQL) of patients. We assessed patient-reported outcomes to characterize the HRQL associated with VTE treatment and to begin to examine those HRQL elements impacting anticoagulation adherence (AA). METHODS: Participants were adult cancer patients with confirmed symptomatic acute lower extremity deep venous thrombosis. Patients were excluded if there was an indication for anticoagulation other than VTE, ECOG performance status >3, or life expectancy < 3 months. Participants were assessed with a self-reported adherence tool. HRQL was measured with a 6-domain questionnaire using a seven-point Likert scale. Evaluations were performed at 30 days and 3 months after enrollment. For the primary objective, an overall adherence rate was calculated at each time point of evaluation. For the HRQL domains, non-parametric testing was used to compare results between subgroups. RESULTS: Seventy-four patients were enrolled. AA and HRQL at 30 days and 3 months were assessed in 50 and 36 participants, respectively. At 30 days the AA rate was 90%, and at 3 months it was 83%. In regard to HRQL, patients suffered frequent and moderate-severe distress in the domains of emotional and physical symptoms, sleep disturbance, and limitations to physical activity. An association between emotional or physical distress and AA was observed. CONCLUSION: Patients with VTE suffer a substantial impairment of their HRQL. Increased emotional distress correlated with better long-term AA. These results can be used to inform additional research aimed at developing novel strategies to improve AA.
Assuntos
Neoplasias , Tromboembolia Venosa , Trombose Venosa , Adulto , Humanos , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologia , Anticoagulantes/uso terapêutico , Qualidade de Vida , Neoplasias/complicaçõesRESUMO
Epidemiological studies suggest that approximately half of the patients with heart failure (HF) have reduced ejection fraction, while the other half have normal ejection fraction (EF). Currently, international guidelines consider QRS duration greater than 130 ms, in the presence of ventricular dysfunction (EF < 35%), as a criterion for selecting patients for cardiac resynchronization therapy (CRT). CRT helps restore intraventricular and auriculoventricular synchrony, improving left ventricular (LV) performance, reducing functional mitral regurgitation, and inducing reverse LV remodeling. This is evidenced by increased LV filling time and left ventricular ejection fraction, decreased LV end-diastolic and end-systolic volumes, mitral regurgitation, and septal dyskinesia. Because the mechanisms of dyssynchrony may be heterogeneous, no single measure may accurately predict response to CRT. Finally, CRT has been progressively shown to be safe and feasible, improves functional status and quality of life, reversely remodels the LV, decreases the number of hospitalizations, total mortality in patients with refractory HF, LV dysfunction, and intraventricular conduction disorders; is a pacemaker-based therapy for HF and thanks to current technology, safe remote monitoring of almost all types of cardiac devices is possible and provides useful alerts in clinical practice.
Los estudios epidemiológicos sugieren que aproximadamente la mitad de los pacientes con insuficiencia cardiaca (IC) tiene fracción de eyección reducida, mientras que la otra mitad, fracción de eyección (FE) normal. Actualmente, las guías internacionales consideran la duración de QRS mayor a 130 ms, en presencia de disfunción ventricular (FE < 35%), como criterio para selección de pacientes a terapia de resincronización cardiaca (TRC). La TRC ayuda a restaurar la sincronía intraventricular y auriculoventricular, mejorando el rendimiento del ventrículo izquierdo (VI), reduciendo la regurgitación mitral funcional e induciendo la remodelación inversa del VI. Esto se evidencia en el aumento del tiempo de llenado del VI y la fracción de eyección del VI, la disminución de los volúmenes telediastólico y telesistólico del VI, y la regurgitación mitral y discinesia septal. Como los mecanismos de la disincronía pueden ser heterogéneos, es posible que ninguna medida prediga con exactitud la respuesta a la TRC. Finalmente, la TRC cardiaca ha demostrado progresivamente ser segura y factible, mejora el estado funcional y la calidad de vida, remodela inversamente el VI, disminuye el número de hospitalizaciones, la mortalidad total en pacientes con IC refractaria, la disfunción ventricular izquierda y los trastornos de conducción intraventricular; es una terapia basada en marcapasos para la IC y gracias a la tecnología actual es posible realizar una supervisión remota y segura de casi todos los tipos de dispositivos cardiacos y obtener alertas útiles en la práctica clínica.
Assuntos
Terapia de Ressincronização Cardíaca , Cardiologia , Insuficiência Cardíaca , Insuficiência da Valva Mitral , Disfunção Ventricular Esquerda , Humanos , Volume Sistólico , América Latina , Qualidade de Vida , Função Ventricular Esquerda , Insuficiência Cardíaca/terapia , Resultado do Tratamento , Remodelação Ventricular/fisiologiaRESUMO
Epidemiological studies suggest that approximately half of the patients with heart failure (HF) have reduced ejection fraction, while the other half have normal ejection fraction (EF). Currently, international guidelines consider QRS duration greater than 130 ms, in the presence of ventricular dysfunction (EF < 35%), as a criterion for selecting patients for cardiac resynchronization therapy (CRT). CRT helps restore intraventricular and auriculoventricular synchrony, improving left ventricular (LV) performance, reducing functional mitral regurgitation, and inducing reverse LV remodeling. This is evidenced by increased LV filling time and left ventricular ejection fraction, decreased LV end-diastolic and end-systolic volumes, mitral regurgitation, and septal dyskinesia. Because the mechanisms of dyssynchrony may be heterogeneous, no single measure may accurately predict response to CRT. Finally, CRT has been progressively shown to be safe and feasible, improves functional status and quality of life, reversely remodels the LV, decreases the number of hospitalizations, total mortality in patients with refractory HF, LV dysfunction, and intraventricular conduction disorders; is a pacemaker-based therapy for HF and thanks to current technology, safe remote monitoring of almost all types of cardiac devices is possible and provides useful alerts in clinical practice.
Los estudios epidemiológicos sugieren que aproximadamente la mitad de los pacientes con insuficiencia cardiaca (IC) tiene fracción de eyección reducida, mientras que la otra mitad, fracción de eyección (FE) normal. Actualmente, las guías internacionales consideran la duración de QRS mayor a 130 ms, en presencia de disfunción ventricular (FE < 35%), como criterio para selección de pacientes a terapia de resincronización cardiaca (TRC). La TRC ayuda a restaurar la sincronía intraventricular y auriculoventricular, mejorando el rendimiento del ventrículo izquierdo (VI), reduciendo la regurgitación mitral funcional e induciendo la remodelación inversa del VI. Esto se evidencia en el aumento del tiempo de llenado del VI y la fracción de eyección del VI, la disminución de los volúmenes telediastólico y telesistólico del VI, y la regurgitación mitral y discinesia septal. Como los mecanismos de la disincronía pueden ser heterogéneos, es posible que ninguna medida prediga con exactitud la respuesta a la TRC. Finalmente, la TRC cardiaca ha demostrado progresivamente ser segura y factible, mejora el estado funcional y la calidad de vida, remodela inversamente el VI, disminuye el número de hospitalizaciones, la mortalidad total en pacientes con IC refractaria, la disfunción ventricular izquierda y los trastornos de conducción intraventricular; es una terapia basada en marcapasos para la IC y gracias a la tecnología actual es posible realizar una supervisión remota y segura de casi todos los tipos de dispositivos cardiacos y obtener alertas útiles en la práctica clínica.
RESUMO
BACKGROUND: Our main objective was to present a multidisciplinary review on the epidemiology of sudden cardiac death (SCD) and the tools that could be used to identify malignant ventricular arrhythmias (VAs) and to perform risk stratification. In addition, indications and contraindications for the use of implantable cardioverter defibrillator (ICD) in general and in special populations including the elderly and patients with chronic kidney disease (CKD) are also given. METHODS: An expert group from the Inter American Society of Cardiology (IASC), through their HF Council (CIFACAH) and Electrocardiology Council (ElectroSIAC), together with the Latin American Heart Rhythm Society (LAHRS), reviewed and discussed the literature regarding the appropriate use of an ICD in people with heart failure (HF) with reduced ejection fraction (HFpEF). Indications and contraindications for the use of ICD are presented in this multidisciplinary review. RESULTS: Numerous clinical studies have demonstrated the usefulness of ICD in both primary and secondary prevention of SCD in HFpEF. There are currently precise indications and contraindications for the use of these devices. CONCLUSIONS: In some Latin American countries, a low rate of implantation is correlated with low incomes, but this is not the case for all Latin America. Determinants of the low rates of ICD implantation in many Latin American countries are still a matter of research. VA remains one of the most common causes of cardiovascular death associated with HFrEF and different tools are available for stratifying the risk of SCD in this population.
Assuntos
Cardiologia , Desfibriladores Implantáveis , Insuficiência Cardíaca , Disfunção Ventricular Esquerda , Humanos , Estados Unidos/epidemiologia , Idoso , Insuficiência Cardíaca/terapia , Insuficiência Cardíaca/complicações , Volume Sistólico , Arritmias Cardíacas/terapia , Morte Súbita Cardíaca/epidemiologia , Disfunção Ventricular Esquerda/complicações , Desfibriladores Implantáveis/efeitos adversos , Fatores de RiscoRESUMO
Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.
Assuntos
Transtornos da Coagulação Sanguínea/etiologia , COVID-19/complicações , Pandemias , SARS-CoV-2 , Transtornos da Coagulação Sanguínea/epidemiologia , COVID-19/epidemiologia , Saúde Global , Humanos , Incidência , Trombose/epidemiologia , Trombose/etiologiaRESUMO
Background: Infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) exhibits a strong infectivity but less virulence compared to severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). In terms of cardiovascular morbidity, susceptible population include elderly and patients with certain cardiovascular conditions. This infection has been associated with cardiac injury, cardiovascular complications and higher mortality. Objectives: The main objective of the CARDIO COVID 19-20 Registry is to determine the presence of cardiovascular comorbidities and cardiovascular complications in COVID-19 infected patients that required in-hospital treatment in different Latin American institutions. Methods: The CARDIO COVID 19-20 Registry is an observational, multicenter, ambispective, and hospital-based registry of patients with confirmed COVID-19 infection who required in-hospital treatment in Latin America. Enrollment of patients started on May 01, 2020 and was initially planned to last three months; based on the progression of pandemic in Latin America, enrollment was extended until December 2020, and could be extended once again based on the pandemic course in our continent at that moment. Conclusions: The CARDIO COVID 19-20 Registry will characterize the in-hospital population diagnosed with COVID-19 in Latin America in order to identify risk factors for worsening of cardiovascular comorbidities or for the appearance of cardiovascular complications during hospitalization and during the 30-day follow up period.
Assuntos
COVID-19/epidemiologia , Doenças Cardiovasculares/epidemiologia , Sistema de Registros , Arritmias Cardíacas/epidemiologia , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/fisiopatologia , COVID-19/complicações , COVID-19/fisiopatologia , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/fisiopatologia , Comorbidade , Doença das Coronárias/epidemiologia , Doença das Coronárias/etiologia , Doença das Coronárias/fisiopatologia , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/etiologia , Insuficiência Cardíaca/fisiopatologia , Humanos , América Latina , Miocardite/epidemiologia , Miocardite/etiologia , Miocardite/fisiopatologia , SARS-CoV-2 , Trombose/epidemiologia , Trombose/etiologia , Trombose/fisiopatologiaRESUMO
BACKGROUND: Neurological complications occur between 50 and 70% of patients with heart transplantation, including cerebrovascular events, infections, seizures, encephalopathy, and neurotoxicity due to pharmacological immunosuppression. Mortality associated with cerebrovascular complications is 7.5% in the first 30 days and up to 5.3% after the first month and up to the first year after transplantation. Case Reports. Three heart-transplanted patients (2 men and 1 woman) treated with tacrolimus were identified. They presented with posterior reversible encephalopathy syndrome on days 5, 6, and 58 posttransplantation, respectively. In these reported cases, no sequelae were observed at 6 months follow-up. CONCLUSIONS: Posterior reversible encephalopathy syndrome as a neurological complication in patients with HT occurred early after the procedure. Early diagnosis and treatment might reduce the risk of serious complications and mortality.
RESUMO
Resumen Introducción: En la población pediátrica, el 95% de las tromboembolias venosas son secundarias a un factor de riesgo; la presencia de catéter venoso central es el factor de riesgo más importante para el desarrollo de trombosis venosa profunda en esta población. Los estudios en población adulta sobre el uso de anticoagulantes se han extrapolado a la población pediátrica, y por ello es importante tener en cuenta las características diferenciales entre ambas poblaciones. Método: Se realizó un estudio descriptivo en el que se revisaron 2300 registros clínicos de pacientes seguidos por la Clínica de Anticoagulación institucional desde 2011 hasta 2019, buscando identificar pacientes menores de 18 años que hubieran recibido manejo anticoagulante ambulatorio. Resultados: Se encontraron 43 pacientes menores de 18 años, el 60% de sexo femenino, con una edad promedio de 9.8 ± 5.2 años. El antecedente patológico más prevalente fueron las valvulopatías (28%). Las principales indicaciones para recibir manejo anticoagulante incluyeron cardiopatías congénitas (21%), prótesis valvular cardíaca mecánica (21%, 5 aórticas y 4 mitrales) y trombosis venosa profunda (14%). La warfarina se utilizó en el 72% de los pacientes. El 81% de los pacientes recibieron tratamiento anticoagulante extendido. Las principales complicaciones durante el tratamiento anticoagulante fueron sangrado ginecológico y cutáneo, así como trombocitopenia. Conclusiones: Las cardiopatías congénitas y las valvulopatías cardíacas son las principales indicaciones para considerar el manejo anticoagulante en la población pediátrica. La warfarina es el medicamento más utilizado en forma ambulatoria en esta población. La adherencia adecuada y el seguimiento ambulatorio en esta población requieren herramientas adicionales para lograr un excelente tratamiento anticoagulante.
Abstract Introduction: In pediatric patients, 95% of venous thromboembolisms are secondary to a risk factor; the presence of central venous catheter is the most important risk factor for the development of deep vein thrombosis in this population. Studies about anticoagulation treatment in adult patients have been extrapolated to the pediatric population, it is important to consider the differential characteristics between these two populations. Method: A descriptive study was conducted; there were reviewed 2300 clinical records of patients followed by the institutional anticoagulation clinic from 2011 to 2019, looking for underage patients who have received ambulatory anticoagulation treatment management. Results: 43 patients under the age of 18 years old were found. 60% were female and the average age was 9.8 ± 5.2 years. The most prevalent pathological antecedent was valve disease (28%). The main indications for anticoagulant treatment included congenital heart disease (21%), mechanical heart valves (21%, 5 aortic and 4 mitral) and deep vein thrombosis (14%). Warfarin was found in 72% of patients. 81% of patients received extended anticoagulation therapy. The main complications during anticoagulant treatment included gynecological and cutaneous bleeding, as well as thrombocytopenia. Conclusions: Congenital heart disease and heart valve disease are the main indications for considering anticoagulation treatment in the pediatric population. Warfarin is the most formulated anticoagulant in this outpatient population. Adequate adherence and outpatient follow-up in requires additional tools to achieve excellent anticoagulant treatment.
RESUMO
Resumen Introducción: La trombosis venosa abdominal es inusual y es una de las formas menos estudiada de la enfermedad tromboembólica venosa. Objetivo: Describir las características epidemiológicas, los factores de riesgo, las complicaciones y el manejo anticoagulante en pacientes con diagnóstico de trombosis venosa abdominal, atendidos en una clínica de anticoagulación en Cali, Colombia. Materiales y método: Estudio descriptivo en el que se identificaron 83 pacientes con diagnóstico de trombosis venosa abdominal, manejados en la clínica de anticoagulación de la Fundación Valle del Lili, entre los años 2011 y 2019. La edad promedio fue de 53.3 ± 17.4 años y el 59% eran de sexo femenino. Fue más frecuente en las venas mesentéricas (19%), seguidas de la vena porta (18%). Los antecedentes incluyen cáncer, hipertensión arterial y estado hipercoagulable/trombofilia. Conclusiones: La trombosis venosa abdominal es una patología poco frecuente. El principal compromiso se presenta en la vena mesentérica. La enoxaparina es el manejo más frecuente. Los pacientes requieren en su mayoría anticoagulación extendida.
Abstract Introduction: Abdominal venous thrombosis is rare condition and is one of the least studied forms of venous thromboembolic disease. Objective: To describe the epidemiological characteristics, risk factors, complications and anticoagulant management in patients with a diagnosis of abdominal venous thrombosis, treated at an anticoagulation clinic in Cali, Colombia. Materials and method: Descriptive study, 83 patients with diagnosis of abdominal venous thrombosis were identified, managed in the anticoagulation clinic of Fundación Valle del Lili, between the years 2011 and 2019. The average age was 53.3 ± 17.4, and 59% female. More frequent in mesenteric veins (19%), followed by portal vein (18%). Personal antecedent includes cancer, high blood pressure, and hypercoagulable/thrombophilia status. Conclusions: Abdominal vein thrombosis is a rare disease. The main compromise occurs at the level of the mesenteric vein. Enoxaparin is the most common management. Most patients require extended anticoagulation.
RESUMO
Resumen Introducción: La enfermedad coronaria es la principal causa de mortalidad en el mundo. Su tratamiento se asocia con una mejor calidad de vida, la cual puede medirse con el cuestionario de MacNew. Objetivo: Establecer los factores determinantes de calidad de vida en pacientes con enfermedad coronaria. Materiales y métodos: Estudio analítico de corte transversal, en el que se usó el cuestionario de MacNew para valorar la calidad de vida en tres dominios: social, emocional y físico. Se incluyeron 249 pacientes con enfermedad coronaria diagnosticada en los años 2004, 2009 o 2013. Los resultados se estratificaron por el tipo de tratamiento (médico, implantación de stent o cirugía de revascularización miocárdica). Se usó un modelo de regresión beta, como una alternativa al modelo de regresión lineal. Resultados: Los puntajes más bajos se asociaron con hipertensión arterial, diabetes mellitus, dislipidemia y aumento del índice de masa corporal. En el dominio físico el puntaje disminuyó en los pacientes mayores de 60 años. El alto grado de escolaridad se asoció con mayores puntajes en todos los dominios. Conclusiones: Los pacientes con enfermedad coronaria presentaron menor calidad de vida asociada a hipertensión arterial, diabetes mellitus, dislipidemia, aumento del índice de masa corporal o mayor edad y mejor calidad de vida asociada con mayor nivel de escolaridad y afiliación al sistema de salud, indiferente a la intervención terapéutica.
Abstract Introduction: Coronary heart disease is the leading cause of mortality worldwide. Its treatment is associated with a better quality of life; it can be measured with the MacNew questionnaire. This study aims to establish the determin. Objective: To stablish the determinants of quality of life in coronary heart disease patients, in Cali, Colombia. Materials and methods: Analytical cross-sectional study, in which the MacNew questionnaire was applied to assess life quality in three domains: social, emotional and physical. 249 patients with coronary heart disease diagnosed in 2004, 2009 or 2013 were included. The results were stratified by type of treatment (doctor, stent implantation or myocardial revascularization surgery). Beta regression model was used, as an alternative to the linear regression model. Results: The MacNew lower scores were associated with hypertension, diabetes mellitus, dyslipidemia and increased body mass index. In the physical domain, the life quality score decreased in patients older than 60 years. High levels of education were associated with higher quality of life scores in all domains. Conclusions: Coronary heart disease patients presented lower quality of life associated with hypertension, diabetes mellitus, dyslipidemia, increased body mass index or older age and better quality of life associated with higher level of education and affiliation to the health system, regardless of the therapeutic intervention received.
Assuntos
Humanos , Masculino , Feminino , Idoso , Doença das Coronárias , Qualidade de Vida , Intervenção Coronária Percutânea , Revascularização MiocárdicaRESUMO
Resumen Introducción: La endocarditis infecciosa es una enfermedad de baja incidencia y alta morbilidad. Puede tener un curso agudo o subagudo, con complicaciones que están directamente relacionadas con la mortalidad y varían según el agente infeccioso; el más frecuente es Staphylococcus aureus. Dependiendo de la condición clínica se puede elegir una terapia antimicrobiana exclusiva o una terapia combinada (antimicrobiana y cirugía); la elección adecuada impacta en las tasas de sobrevida. Objetivo: Describir las características clínicas, microbiológicas y ecocardiográficas en pacientes con endocarditis infecciosa y analizar la mortalidad según el tratamiento recibido (terapia antimicrobiana o terapia combinada). Método: Estudio de cohorte retrospectivo, realizado en el Hospital Universitario Fundación Valle del Lili, en Cali, Colombia, en el que se incluyeron pacientes hospitalizados mayores de 18 años que cumplían los criterios de Duke modificados para diagnóstico de endocarditis infecciosa. Se evaluaron dos cohortes según hubieran recibido tratamiento antimicrobiano exclusivo o terapia combinada. Los pacientes fueron seguidos hasta el egreso hospitalario. Resultados: De 101 pacientes, 58 recibieron terapia antimicrobiana y 43 terapia combinada. La sobrevida global fue del 77.35%; el grupo de terapia combinada tuvo una hazard ratio ajustada de 0.13 (intervalo de confianza del 95%: 0.036-0.505; p = 0.003). La tasa de mortalidad calculada por 1000 días-persona fue de 25.9 con terapia antimicrobiana y de 4.33 con terapia combinada. Conclusiones: El grupo de terapia combinada tuvo más complicaciones y mayor estancia en la unidad de cuidados intensivos, pero menores tasas de mortalidad que los pacientes con terapia antimicrobiana exclusiva. De acuerdo con las indicaciones actuales de manejo quirúrgico descritas en las guías internacionales, se pueden obtener excelentes resultados en los pacientes más enfermos.
Abstract Introduction: Infective endocarditis is a disease of low incidence but high morbidity. It can have an acute or subacute course, with complications that are directly related to mortality and vary according to the infectious agent; the most common is Staphylococcus aureus. Based on the clinical condition, an exclusive antimicrobial therapy or a combined therapy (antimicrobial and surgery) can be chosen; their proper choice impacts survival rates. Objective: To describe the clinical, microbiological and echocardiographic characteristics in patients with infective endocarditis and to analyze how mortality behaved according to the treatment received (antimicrobial therapy or combined therapy). Method: A retrospective cohort study, carried out at the Fundación Valle del Lili University Hospital, Cali, Colombia, which included hospitalized patients over 18 years of age who met modified Duke criteria for the diagnosis of infective endocarditis. Two cohorts were evaluated according to treatment: exclusive antimicrobial and combined therapy. They were followed until discharge from the hospital. Results: Of 101 patients, 58 received antimicrobial therapy and 43 combined therapy. Overall survival was 77.35%, the combined therapy group had an adjusted hazard ratio of 0.13 (95% confidence interval: 0.036-0.505; p = 0.003). The mortality rate calculated per 1000 person-days was 25.9 in antimicrobial therapy and 4.33 in combination therapy. Conclusions: the combined therapy group had more complications and a longer hospital stay in the ICU, but lower mortality rates than the patients on exclusive antimicrobial therapy. According to the current indications for surgical management described in international guidelines, excellent results can be obtained in sicker patients.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Endocardite , Cirurgia Geral , Mortalidade , Insuficiência CardíacaRESUMO
Resumen Introducción La enfermedad por coronavirus 2019 (COVID-19) puede predisponer a tromboembolia venosa o trombosis arterial debido a una respuesta inflamatoria aumentada, hipoxia, inmovilización y coagulación intravascular diseminada; hasta en un 20 a 50% de pacientes hospitalizados con COVID-19 tienen alteraciones hematológicas relacionadas con coagulopatía (dímero D elevado, tiempo de protrombina prolongado, trombocitopenia y/o fibrinógeno bajo). Evaluaciones post mortem evidencian depósitos trombóticos microvasculares típicos, ricos en plaquetas en vasos pequeños de pulmones y otros órganos. Objetivo Brindar una aproximación práctica y actualizada en el manejo del paciente con riesgo elevado o que presentan eventos tromboembólicos en el marco de la actual pandemia por COVID-19. Material y métodos: Se realizó una revisión narrativa que incluyó estudios observacionales descriptivos. Se efectuó una búsqueda de la literatura de evidencia médica en diferentes buscadores como Science Direct y PubMed, usando las palabras claves thromboprophylaxis, anticoagulation, thrombosis, anticoagulant, COVID-19, SARS-CoV-2, coronavirus. Posteriormente se escribieron las recomendaciones generales referentes al tema. Conclusiones Existen diferentes formas en las que la pandemia por COVID-19 puede predisponer al desarrollo de enfermedades trombóticas o tromboembólicas, el efecto directo o indirecto de este virus relacionado con la tormenta de citocinas que precipita el inicio del síndrome de respuesta inflamatoria sistémica y predispone al desarrollo de eventos trombóticos; también las intervenciones disponibles pueden tener interacciones farmacológicas con antiagregantes y/o anticoagulantes.
Abstract Introduction Coronavirus 19 infection can predispose to VTE or arterial thrombosis due to a heightened inflammatory response, hypoxia, immobility and DIC. Up to 20-50% of hospitalized patients with COVID-19 have hematological disorders related to coagulopathies (elevated D-dimer, prolonged PT, thrombocytopenia and/or low fibrinogen). Post-mortem examinations show typical platelet-rich microvascular thrombotic deposits in the small vessels of the lungs and other organs. Objective To provide a practical, updated approach to the treatment of patients at high risk for or with ongoing thromboembolic events in the current COVID-19 pandemic setting. Material and methods A narrative review was performed including descriptive observational studies. A search of the medical evidence literature was carried out in different search engines such as ScienceDirect and PubMed, using the following key words: thromboprophylaxis, anticoagulation, thrombosis, anticoagulant, COVID-19, SARS-CoV-2, and coronavirus, and general recommendations on the topic were subsequently composed. Conclusions The are various ways in which the COVID-19 pandemic may predispose to the development of thrombotic or thromboembolic diseases. The virus may have a direct or indirect effect related to the cytokine storm which triggers the onset of systemic inflammatory response syndrome and predisposes to the development of thrombotic events. The available interventions may also have pharmacological interactions with antiplatelet drugs and/or anticoagulants.
Assuntos
Humanos , Transtornos da Coagulação Sanguínea , Trombose , COVID-19 , AnticoagulantesRESUMO
Resumen Introducción: en el trasplante cardiaco la sobrevida es del 81 al 85% en el primer año; las infecciones y la falla del injerto son las principales causas de mortalidad. Objetivo: determinar los factores de riesgo asociados a mortalidad al año postrasplante cardiaco en un hospital de alta complejidad del suroccidente colombiano. Métodos: cohorte retrospectiva de pacientes con trasplante de corazón llevado a cabo entre 1996 a 2015. Se obtuvo la información de las características del donante, receptor y procedimiento quirúrgico. Se realizó una regresión de Cox; el evento de interés fue la mortalidad al primer año de seguimiento. En el análisis multivariable se incluyeron variables con p ≤ 0,20 y significancia clínica. Resultados: se incluyeron 158 pacientes, con mediana de edad de 50 años (RIC: 39-57), 76% hombres. La principal etiología de falla cardiaca fue idiopática (45%). La mediana de tiempo de isquemia fue 187 minutos (RIC: 142-300). La mortalidad fue 24%, y se atribuyó principalmente a infecciones (29%). Fueron factores asociados a mortalidad la cardiopatía congénita como etiología de falla cardíaca (p 0,048), antecedente de diabetes mellitus (p 0,001), cirugía cardiaca previa (p 0,023) tiempo de isquemia mayor a 150 minutos (p 0,038) y relación receptor hombre/donante mujer (p 0,022). Conclusiones: los factores asociados a mayor mortalidad en el primer año postrasplante cardiaco fueron: etiología de la falla cardíaca por cardiopatía congénita, antecedente de diabetes mellitus, cirugía cardiaca previa, relación receptor hombre con donante mujer, tiempo de isquemia mayor a 150 minutos.
Abstract Introduction: The survival rate in the first year after heart transplant is between 81% and 85%. The main causes of mortality are infections and failure of the graft. Objective: To determine the risk factors associated with mortality at one year post- cardiac transplant in a high complexity hospital in south-west Colombia. Methods: A retrospective cohort study was performed on patients with a heart transplant carried out between 1996 and 2015. Information was obtained on the characteristics of the donor, recipient, and surgical procedure. A Cox regression was performed, with the event of interest being mortality in the first year of follow-up. In the multivariate analysis, variables were included that had a P≤ .20 and clinical significance. Results: The study included a total of 158 patients, with a median age of 50 years (IQR: 39-57), of whom 76% were males. The most common origin was idiopathic heart failure (45%). The median time of ischaemia was 187 minutes (IQR: 142-300). The mortality was 24% and was mainly due to infections (29%). There were factors associated with the congenital heart failure mortality such as origin of heart failure (P = .048), history of diabetes mellitus (P = .001), previous cardiac surgery (P = .023), ischaemia time greater than 150 minutes (P = .038), and the male recipient / female donor ratio (P = .022). Conclusions: The factors associated with higher mortality in the first year post-cardiac transplant were: origin of heart failure due to congenital heart disease, history of diabetes mellitus, previous cardiac surgery, the male recipient / female donor ratio, and an ischaemia time greater than 150 minutes.